companydata.dkCABA APS: Financial statements 2019
CVR: 39691825
CABA APS (CVR 39691825) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125. Equity amounted to DKK 43,750. The solvency ratio was 87.5%.
- Gross Profit
- -3,125 kr.
- Profit/Loss
- -3,125 kr.
- Equity
- 43,750 kr.
- Total Assets
- 50,000 kr.
- Employees
- 0
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
CABA APS has published its interim report for the period June 18, 2018 – December 31, 2018.
As of April 16, 2019, Søren Luplau-Pagh is registered as director of CABA APS.
As of April 16, 2019, Morten Olesen has stepped down as director of CABA APS.
As of April 16, 2019, Stephan Dr Braun has stepped down as director of CABA APS.
About CABA APS
CABA APS is a Danish company of the type Anpartsselskab based in Fårevejle, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ACBA APS. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company is owned by Devopharma ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity amounted to DKK 25,000.